아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - ciprofloxacinum hýdróklóríð - tafla - 500 mg

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamíð - blöðruhálskirtli - innkirtla meðferð - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz gmbh* - rifampicinum inn - hart hylki - 300 mg

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz gmbh* - rifampicinum inn - hart hylki - 150 mg

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

pharmanovia a/s - opium - dropar til inntöku, lausn - 10 mg/ml

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

evolan pharma ab - melatoninum inn; sucralose - mixtúra, lausn - 1 mg/ml

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

jazz pharmaceuticals ireland ltd - delta-9-tetrahydrocannabinolum; cannabidiolum inn - munnholsúði, lausn - 27 mg/ml + 25 mg/ml

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

eurovet animal health b.v. - chlortetracycline hydrochloride - húðúði, dreifa - 78,6 mg/g

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - quizartinib dihydrochloride - kyrningahvítblæði, mergbólga - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.